114 related articles for article (PubMed ID: 31738155)
21. Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency.
Schmitz M; Candelise N; Kanata E; Llorens F; Thüne K; Villar-Piqué A; da Silva Correia SM; Dafou D; Sklaviadis T; Appelhans D; Zerr I
Mol Neurobiol; 2020 Apr; 57(4):1863-1874. PubMed ID: 31848935
[TBL] [Abstract][Full Text] [Related]
22. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
Bailón E; Ugarte-Berzal E; Amigo-Jiménez I; Van den Steen P; Opdenakker G; García-Marco JA; García-Pardo A
J Leukoc Biol; 2014 Aug; 96(2):185-99. PubMed ID: 25080557
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine.
Gorzkiewicz M; Deriu MA; Studzian M; Janaszewska A; Grasso G; Pułaski Ł; Appelhans D; Danani A; Klajnert-Maculewicz B
Biomacromolecules; 2019 Mar; 20(3):1429-1442. PubMed ID: 30707833
[TBL] [Abstract][Full Text] [Related]
26. Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Perez-Chacon G; Martinez-Laperche C; Rebolleda N; Somovilla-Crespo B; Muñoz-Calleja C; Buño I; Zapata JM
Clin Cancer Res; 2016 Jan; 22(1):134-45. PubMed ID: 26324744
[TBL] [Abstract][Full Text] [Related]
27. Novel agents in chronic lymphocytic leukemia.
Lamanna N; O'Brien S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):137-145. PubMed ID: 27913472
[TBL] [Abstract][Full Text] [Related]
28. The treatment of relapsed refractory chronic lymphocytic leukemia.
Brown JR
Hematology Am Soc Hematol Educ Program; 2011; 2011():110-8. PubMed ID: 22160021
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.
Kay NE; Han L; Bone N; Williams G
Br J Haematol; 2001 Mar; 112(3):760-7. PubMed ID: 11260081
[TBL] [Abstract][Full Text] [Related]
30. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers.
Agashe HB; Babbar AK; Jain S; Sharma RK; Mishra AK; Asthana A; Garg M; Dutta T; Jain NK
Nanomedicine; 2007 Jun; 3(2):120-7. PubMed ID: 17572354
[TBL] [Abstract][Full Text] [Related]
31. [Molecular biology examination in chronic lymphocytic leukemia].
Telek B; Rejtó L; Mezei G; Karászi E; Kappelmayer J; Balázs M; Kiss A; Ujj G; Rák K; Udvardy M
Orv Hetil; 2001 Apr; 142(16):833-7. PubMed ID: 11340945
[TBL] [Abstract][Full Text] [Related]
32. Key issues in the treatment of chronic lymphocytic leukaemia (CLL).
Catovsky D; Murphy RL
Eur J Cancer; 1995 Dec; 31A(13-14):2146-54. PubMed ID: 8652233
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of amyloid and prion fibril formation in the absence and presence of dense shell sugar-decorated dendrimers.
Ottaviani MF; Cangiotti M; Fiorani L; Fattori A; Wasiak T; Appelhans D; Klajnert B
Curr Med Chem; 2012; 19(34):5907-21. PubMed ID: 22834819
[TBL] [Abstract][Full Text] [Related]
34. The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
Albano F; Chiurazzi F; Mimmi S; Vecchio E; Pastore A; Cimmino C; Frieri C; Iaccino E; Pisano A; Golino G; Fiume G; Mallardo M; Scala G; Quinto I
Cell Death Dis; 2018 Jan; 9(1):13. PubMed ID: 29317636
[TBL] [Abstract][Full Text] [Related]
35. [SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
Vargas Núñez JA
An R Acad Nac Med (Madr); 2014; 131(2):441-56. PubMed ID: 27400564
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Internalization of Maltose-Modified Poly(propyleneimine) Glycodendrimers into Leukemic Cell Lines.
Studzian M; Szulc A; Janaszewska A; Appelhans D; Pułaski Ł; Klajnert-Maculewicz B
Biomacromolecules; 2017 May; 18(5):1509-1520. PubMed ID: 28414464
[TBL] [Abstract][Full Text] [Related]
37. Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept.
Almeida AR; Correia DV; Fernandes-Platzgummer A; da Silva CL; da Silva MG; Anjos DR; Silva-Santos B
Clin Cancer Res; 2016 Dec; 22(23):5795-5804. PubMed ID: 27307596
[TBL] [Abstract][Full Text] [Related]
38. [Ultra high risk chronic lymphocytic leukemia - characteristics and treatment options].
Lysák D; Jindra P
Vnitr Lek; 2013 Oct; 59(10):887-94. PubMed ID: 24164366
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
Sharma S; Rai KR
Cancer; 2019 May; 125(9):1432-1440. PubMed ID: 30807655
[TBL] [Abstract][Full Text] [Related]
40. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
